STOCK TITAN

Moringa Acquisition Corp - MACAU STOCK NEWS

Welcome to our dedicated page for Moringa Acquisition news (Ticker: MACAU), a resource for investors and traders seeking the latest updates and insights on Moringa Acquisition stock.

Moringa Acquisition Corp (MACAU) is a blank check company focused on effecting a merger or business combination with Israel-related technology companies. Recently, Moringa announced a proposed merger with Silexion Ltd, an oncology-focused biotechnology company. Silexion's product, Loder™, has shown promising results in a Phase 2a clinical trial for non-resectable pancreatic cancer. The business combination is expected to close in the third quarter of 2024, subject to customary closing conditions and regulatory approvals.

Rhea-AI Summary
Silexion, a biotech company, successfully tested its product Loder™ in a Phase 2a clinical trial for pancreatic cancer, showing a significant survival advantage. Moringa Acquisition Corp (Nasdaq: MACA) announced a business combination with Silexion, valuing the company at $62.5 million. The merger aims to list Silexion on Nasdaq, offering shareholders a chance to invest in its promising RNA therapeutics platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Moringa Acquisition Corp (Nasdaq: MACA) announced an extraordinary general meeting to extend the date for an initial business combination. The sponsor will make additional contributions to the trust account if the extension is approved. The contributions will be $15,000 or $0.025 per public share each month until the new termination date. The company will liquidate if the sponsor fails to make a contribution. The contributions will be repayable upon a business combination or forfeited if no combination is made. The trust account proceeds will be invested in U.S. government treasury bills or money market funds. More information can be found in the definitive proxy statement and supplement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Moringa Acquisition Corp (NASDAQ: MACA) announced the adjournment of its Extraordinary Meeting, initially scheduled for February 7, 2023, to February 9, 2023. This meeting aims to vote on extending the deadline for completing a business combination from February 19, 2023, to August 19, 2023. Shareholders are advised to participate and review the Definitive Proxy Statement filed with the SEC. The company previously entered into a business combination agreement with Holisto Ltd., a tech-powered travel agency. The record date for shareholders to vote remains January 3, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
-
Rhea-AI Summary

On June 13, 2022, Holisto Ltd and Moringa Acquisition Corp (Nasdaq: MACA) announced a merger agreement, enabling Holisto to become publicly listed. The combination values Holisto at approximately $405 million and provides non-redeeming Moringa shareholders with a bonus of up to 1,725,000 shares. Holisto, leveraging AI technology, aims to disrupt the $194 billion online hotel booking market with personalized offerings. The transaction is expected to close in Q4 2022, subject to shareholder and Nasdaq approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.1%
Tags
-
Rhea-AI Summary

Moringa Acquisition Corp (NasdaqCM: MACA, MACAU, MACAW) filed its annual report on Form 10-K for the year ended December 31, 2021, with the SEC on March 31, 2022. This report is accessible through their official website and the SEC's site. The company targets mergers and acquisitions, particularly focusing on technology firms related to Israel. The press release also includes a reminder that forward-looking statements are based on management's beliefs and assumptions, and actual results may differ due to various factors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
-
Rhea-AI Summary

Moringa Acquisition Corp has announced the pricing of its initial public offering (IPO) at $10.00 per unit, totaling 10,000,000 units. The units will be listed on Nasdaq under the symbol 'MACAU' starting February 17, 2021. Each unit includes one Class A ordinary share and one-half of a redeemable warrant, allowing the purchase of additional shares at $11.50. The Company aims to focus on Israel-related technology firms and has engaged EarlyBirdCapital, Inc. and Moelis & Company as joint book-running managers. A registration statement was approved by the SEC on February 16, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is the current stock price of Moringa Acquisition (MACAU)?

The current stock price of Moringa Acquisition (MACAU) is $13.05 as of February 7, 2025.

What is Moringa Acquisition Corp (MACAU)?

Moringa Acquisition Corp is a blank check company focused on merging with Israel-related technology companies.

What recent announcement did Moringa make?

Moringa announced a proposed merger with Silexion Ltd, an oncology-focused biotechnology company.

What is Silexion's product Loder™?

Loder™ is Silexion's first-generation product showing promising results in a Phase 2a clinical trial for non-resectable pancreatic cancer.

When is the business combination expected to close?

The business combination is expected to close in the third quarter of 2024, subject to regulatory approvals.

Who is the CEO of Moringa Acquisition Corp?

Ilan Levin is the Chief Executive Officer and Chairman of Moringa Acquisition Corp.

How many shares will Moringa issue to Silexion's current equity holders?

Moringa will issue 6.25 million shares (on a fully-diluted basis) to Silexion's current equity holders.

How many members will be on the combined company's board of directors?

The combined company's board of directors will consist of seven members, two appointed by Moringa's sponsor.

What is the focus of Silexion Therapeutics?

Silexion Therapeutics is focused on developing innovative treatments for solid tumor cancers with the mutated KRAS oncogene.

Who are the legal counsels for Moringa Acquisition Corp and Silexion?

Meitar | Law Offices and Greenberg Traurig are legal counsels for Moringa, and Herzog Fox & Neeman is the legal counsel for Silexion.

Where can shareholders find more information about the proposed business combination?

Shareholders can find more information on the SEC's website or the Investor Relations section of the Moringa website.
Moringa Acquisition Corp

Nasdaq:MACAU

MACAU Rankings

MACAU Stock Data

11.98M
0.01%
Shell Companies
Blank Checks
Link
United States
NEW YORK